Ulla Engstrom

Title: Ulla Engstrom: Innovator in Platelet Derived Growth Factor Research

Introduction

Ulla Engstrom is a prominent inventor based in Uppsala, Sweden. She has made significant contributions to the field of biochemistry, particularly in the area of platelet derived growth factors. With a total of 2 patents, her work has the potential to impact medical research and therapeutic applications.

Latest Patents

Engstrom's latest patents include innovations related to platelet derived growth factor antagonists and agonists. The first patent describes antagonists for PDGF, which contain amino acids and may exist as monomers or dimers. Notably, the dimers bind to PDGF receptors but prevent the dimerization of the bound receptors, which is essential for PDGF's effect. This antagonistic effect could lead to new therapeutic strategies. The second patent focuses on PDGF modifiers, which are peptides derived from wild type PDGF monomers. These peptides function as either agonists or antagonists and have various applications, including methods for causing receptor dimerization and autophosphorylation in cells with PDGF-.beta. receptors.

Career Highlights

Ulla Engstrom is affiliated with the Ludwig Institute for Cancer Research Limited, where she continues her research and development in the field of cancer biology. Her work is characterized by a strong focus on the molecular mechanisms of growth factors and their implications in cancer treatment.

Collaborations

Engstrom collaborates with notable colleagues, including Maria Andersson and Gudrun Backstrom. These partnerships enhance her research capabilities and contribute to the advancement of knowledge in her field.

Conclusion

Ulla Engstrom's innovative work in platelet derived growth factors exemplifies the intersection of science and technology in addressing complex medical challenges. Her patents reflect a commitment to advancing therapeutic options in cancer research.